HHS outlined details of a revised 340B rebate pilot allowing some drug manufacturers to deny rebates for a subset of products, after earlier implementation approaches faced scrutiny. The changes reflect continued balancing between cost containment goals and the program’s role in supporting safety-net providers. Pharma groups backed the updated pilot framework, signaling continued negotiation over how 340B adjustments should preserve access while refining rebate mechanics.